Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Contemporary protease inhibitors and cardiovascular risk
Jens Lundgren
, Amanda Mocroft, Lene Ryom
Department of Clinical Medicine
13
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Contemporary protease inhibitors and cardiovascular risk'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Protease Inhibitors
100%
Cardiovascular Risk
100%
Atazanavir
50%
Cardiovascular Disease
50%
Darunavir
50%
Conservative Approach
25%
Controlled Experiment
25%
Underlying Risk
25%
Ritonavir
25%
Cardioprotection
25%
Biological Explanations
25%
Bilirubin Level
25%
Biological Mechanisms
25%
Long-term Exposure
25%
Randomized Trial
25%
Lipid Accumulation
25%
HIV+
25%
Increasing Risk
25%
Excess Risk
25%
Everyday Practices
25%
HIV Protease Inhibitors
25%
Macrophages
25%
Clinical Disease
25%
Lipid Metabolism
25%
Medicine and Dentistry
Cardiovascular Disease
100%
Proteinase Inhibitor
100%
Cardiovascular Risk
100%
Atazanavir
40%
Darunavir
40%
Individualization
20%
Lipid Storage
20%
Diseases
20%
Human immunodeficiency virus
20%
Bilirubin
20%
Macrophage
20%
Observational Study
20%
Effect Size
20%
Lipid Metabolism
20%
Human Immunodeficiency Virus Proteinase Inhibitor
20%
Ritonavir
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
100%
Cardiovascular Disease
100%
Proteinase Inhibitor
100%
Darunavir
40%
Atazanavir
40%
Ritonavir
20%
Diseases
20%
Bilirubin
20%
Human Immunodeficiency Virus Proteinase Inhibitor
20%
Cholesterol Derivative
20%
Observational Study
20%
HIV
20%